---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-046572"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:34:20.496860+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PepGen reports preclinical data: PGN-EDODM1 corrects 99% of mis-splicing in DM1 mouse model

## Summary
- EDO platform delivers 25-fold higher oligonucleotide to myotube nuclei vs naked in vitro.
- 72% of skeletal muscle nuclei in NHPs positive for oligo after two 30 mg/kg doses.
- Single dose of PGN-EDODM1 reversed 76% myotonia and corrected 68% mis-splicing in DM1 mouse.
- Four doses reversed 99% myotonia and corrected 99% mis-splicing; well-tolerated.
- PGN-EDO51 safety in humans: transient, mild, reversible TEAEs at 5 and 10 mg/kg.

## SEC filing metadata
- accession: 0000950170-23-046572
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017023046572/0000950170-23-046572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017023046572/pepg-20230906.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-046572
- JSON: https://secwatch.observer/filing/0000950170-23-046572.json
- Plain text: https://secwatch.observer/filing/0000950170-23-046572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.